ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 120 filers reported holding ARBUTUS BIOPHARMA CORP in Q1 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $998,194 | -11.7% | 491,721 | 0.0% | 0.02% | -4.0% |
| Q2 2023 | $1,130,958 | -40.2% | 491,721 | -21.2% | 0.02% | -35.9% |
| Q1 2023 | $1,890,681 | +13.9% | 623,987 | -12.4% | 0.04% | +2.6% |
| Q4 2022 | $1,660,514 | +13.3% | 712,667 | -7.1% | 0.04% | +2.7% |
| Q3 2022 | $1,466,000 | -2.1% | 767,400 | +39.0% | 0.04% | -5.1% |
| Q2 2022 | $1,497,000 | +2.4% | 552,268 | +12.6% | 0.04% | +14.7% |
| Q1 2022 | $1,462,000 | -18.0% | 490,623 | +7.0% | 0.03% | -19.0% |
| Q4 2021 | $1,784,000 | +11.6% | 458,642 | +23.1% | 0.04% | -4.5% |
| Q3 2021 | $1,598,000 | +778.0% | 372,700 | +521.2% | 0.04% | +633.3% |
| Q2 2021 | $182,000 | +26.4% | 60,000 | +38.8% | 0.01% | +20.0% |
| Q1 2021 | $144,000 | -14.3% | 43,218 | -8.6% | 0.01% | -16.7% |
| Q4 2020 | $168,000 | +309.8% | 47,280 | +257.7% | 0.01% | +200.0% |
| Q3 2020 | $41,000 | -30.5% | 13,218 | -37.8% | 0.00% | -60.0% |
| Q4 2019 | $59,000 | -83.1% | 21,261 | -55.7% | 0.01% | -83.3% |
| Q2 2018 | $350,000 | – | 48,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 340,000 | $1,459,000 | 0.53% |
| RTW INVESTMENTS, LP | 4,733,323 | $20,306,000 | 0.31% |
| APIS CAPITAL ADVISORS, LLC | 70,000 | $300,000 | 0.29% |
| Hudson Bay Capital Management LP | 1,800,000 | $7,722,000 | 0.10% |
| COWEN AND COMPANY, LLC | 249,215 | $1,069,000 | 0.05% |
| Kerrisdale Advisers, LLC | 100,000 | $429,000 | 0.05% |
| Woodline Partners LP | 496,172 | $2,129,000 | 0.04% |
| Shay Capital LLC | 60,000 | $257,000 | 0.03% |
| Walleye Capital LLC | 231,037 | $991,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 212,700 | $912,000 | 0.02% |